PTEN and prostate cancer: Synergy was observed in the Pten/Trp53-deficient prostate cancer cell line, although to a lesser degree than the Pten-deficient cell with wildtype Trp53. In the early-stage intervention models, we did not see appreciable improvement after adding GSK690693 to apalutamide.